SOURCE-LINKED STUDY SUMMARY
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Abstract summarizedQuality not appraised
- What was studied
- Randomized trial comparing liraglutide with placebo for weight loss, with lifestyle counseling in both groups.
- Who / model studied
- 3731 adults without type 2 diabetes, with obesity or overweight plus abnormal blood lipids or hypertension; treatment lasted 56 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- All primary weight outcomes favored liraglutide: average loss was 8.4 versus 2.8 kg; 63.2% versus 27.1% lost at least 5%, and 33.1% versus 10.6% lost more than 10%. Mild or moderate nausea and diarrhea were common. Serious events occurred in 6.2% versus 5.0%.
- Limitations & context
- The reported weight analysis filled missing values by carrying forward the last recorded observation.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa1411892